Price$11.59+0.36 (+3.16%)
01:30 PM07:45 PM
News · 26 weeks46+100%
2026-04-192026-10-11
Mix3790d
- Insider24(65%)
- SEC Filings7(19%)
- Other3(8%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- PRAngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver CancerPolicy Applies Medical Necessity Criteria Across Medicare Administrative Contractor (MAC) Jurisdictions for Eligible Prostate and Liver Cancer Patients AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation technology delivered by AngioDynamics’ NanoKnife System, for eligible patients wi
- SECSEC Form 10-Q filed by AngioDynamics Inc.10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
- SECSEC Form DEFA14A filed by AngioDynamics Inc.DEFA14A - ANGIODYNAMICS INC (0001275187) (Filer)
- SECSEC Form DEF 14A filed by AngioDynamics Inc.DEF 14A - ANGIODYNAMICS INC (0001275187) (Filer)
- SECSEC Form 8-K filed by AngioDynamics Inc.8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- SECSEC Form 8-K filed by AngioDynamics Inc.8-K - ANGIODYNAMICS INC (0001275187) (Filer)
- PRAngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and ProfitabilityDelivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million 6.9% Med Tech Net Sales $39.9 million 13.2% Med Device
- PRAngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive OfficerMedical Technology Executive Brings More than 20 years of Leadership Experience, Including Cardiovascular, Endovascular and Oncology Markets, with a Track Record of Accelerating Growth and Improving Profitability Jim Clemmer to Retire Following Ten Years as President and Chief Executive Officer AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026.
- PRAngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism EvidenceInvestigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT Consortium®, will evaluate CT pulmonary angiography radiomics as predictors of thrombus biology, thromb
- SECAmendment: SEC Form 10-K/A filed by AngioDynamics Inc.10-K/A - ANGIODYNAMICS INC (0001275187) (Filer)
- SECAmendment: SEC Form 10-K/A filed by AngioDynamics Inc.10-K/A - ANGIODYNAMICS INC (0001275187) (Filer)
- PRAngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.an
- INSIDERSVP Quality and Regulatory Nighan Warren Jr sold $344,006 worth of shares (23,370 units at $14.72), decreasing direct ownership by 27% to 64,745 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- PRAngioDynamics to Participate in Upcoming Investor ConferencesAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 46th Annual Growth Conference Presentation: Tuesday, August 11, 2026 from 3:30-3:55 PM ET A live webcast of the presentation will be accessible through the "Investors" section of the Company’s website at www.angiodynamics.com. Abou
- INSIDERSVP International Piccinini Laura converted options into 8,047 shares and covered exercise/tax liability with 4,506 shares, increasing direct ownership by 5% to 81,929 units (SEC Form 4) (tax withholding)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDEREVP and CFO Trowbridge Stephen A converted options into 16,296 shares and covered exercise/tax liability with 8,319 shares, increasing direct ownership by 3% to 305,796 units (SEC Form 4) (tax withholding)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERPresident and CEO Clemmer James C converted options into 52,358 shares and covered exercise/tax liability with 26,728 shares, increasing direct ownership by 3% to 862,448 units (SEC Form 4) (for withholding tax)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERSVP Quality and Regulatory Nighan Warren Jr converted options into 5,694 shares and covered exercise/tax liability with 1,671 shares, increasing direct ownership by 5% to 88,115 units (SEC Form 4) to satisfy withholding obligation4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERSVP/GM, Vascular Access Campbell Chad Thomas converted options into 6,466 shares and covered exercise/tax liability with 2,330 shares, increasing direct ownership by 4% to 108,676 units (SEC Form 4) to satisfy withholding obligation4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERDirector Johnson Wesley was granted 11,887 shares, increasing direct ownership by 8% to 155,425 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERSVP Quality and Regulatory Nighan Warren Jr was granted 17,966 shares, increasing direct ownership by 27% to 84,092 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERDirector Burgess Lorinda was granted 11,887 shares, increasing direct ownership by 22% to 67,144 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERDirector Reed Jan Stern was granted 11,887 shares, increasing direct ownership by 11% to 116,921 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERDirector Auen Eileen O'Shea was granted 11,887 shares, increasing direct ownership by 11% to 116,605 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
- INSIDERDirector Licitra Karen A was granted 11,887 shares, increasing direct ownership by 13% to 102,322 units (SEC Form 4)4 - ANGIODYNAMICS INC (0001275187) (Issuer)
ANGO FAQ
7 questionsWhat does AngioDynamics Inc. do?
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's...Where does ANGO stock trade?
AngioDynamics Inc. (ANGO) is listed on NASDAQ.What sector and industry is ANGO in?
AngioDynamics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did AngioDynamics Inc. go public?
AngioDynamics Inc. (ANGO) completed its IPO in 2004.What are analysts saying about ANGO?
AngioDynamics Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $2400.00 price target on 2025-07-16. Recent price targets range from $1200.00 to $3700.00.What companies are similar to ANGO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ANGO side-by-side with any of them on Quantisnow.How can I track ANGO on Quantisnow?
Quantisnow aggregates AngioDynamics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANGO to receive live email and push alerts on every new disclosure.